My personal view is that stockouts of generic drugs are unfortunately to be expected, and happen in the US (http://www.nytimes.com/2012/02/11/health/policy/supply-of-methotrexate-a-cancer-drug-may-run-out-soon.html?_r=2&) as well as Indonesia.

Original manufacturer firm exit upon brand expiration and generic firm entry can reduce supply capacity, low profit margins in the eventual generic production & distribution business are insufficient to sustain adequately stocked supply chains and inventories (and sometimes inadequate to sustain good manufacturing practices), and longer supply chains are also common.

This is, as always, reducible to a trade-off between greater investment pre-expiry versus less post-expiry, between more expensive, more restricted but more reliable access before versus after expiry, and ultimately between welfare gains among the current generation of patients benefiting from generics versus welfare losses among future generations from lower innovation in the present.

Practical solutions for Indonesia might be to think about some investments by Indonesia in home-grown generic manufacturing, a regional cooperative to share capacity and overcome local stockouts, having the government look at purchasing excess EU stock (or US http://www.goodrx.com/methotrexate) perhaps under foreign aid programs, or using charitable foundations to fund this very worthwhile and affordable investment in a sick child's future...